AQR Capital Management
GSK icon

AQR Capital Management’s GSK GSK Stock Holding History

AQR Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1M Buy
346,157
+63,034
+22% +$3.33M 0.01% 1234
2026
Q1 		$15.6M Buy
283,123
+46,521
+20% +$2.52M 0.01% 1131
2025
Q4 		$11.6M Buy
236,602
+32,996
+16% +$1.54M 0.01% 1146
2025
Q3 		$8.79M Buy
203,606
+150,316
+282% +$5.87M 0.01% 1158
2025
Q2 		$2.05M Buy
53,290
+13,051
+32% +$499K ﹤0.01% 1755
2025
Q1 		$1.56M Buy
40,239
+18,420
+84% +$674K ﹤0.01% 1748
2024
Q4 		$738K Sell
21,819
-5,636
-21% -$203K ﹤0.01% 2057
2024
Q3 		$1.12M Buy
27,455
+1,092
+4% +$44.7K ﹤0.01% 1780
2024
Q2 		$1.01M Buy
26,363
+13,403
+103% +$564K ﹤0.01% 1746
2024
Q1 		$556K Buy
+12,960
New +$534K ﹤0.01% 1924

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management's GSK Position: Q2 2026 in Review

AQR Capital Management increased its GSK (GSK) stake by 22% in Q2 2026, buying an estimated $3.33M and bringing the position to 346,157 shares worth $18.1M. The position accounts for 0.01% of the portfolio, ranked #1234.

AQR Capital Management first reported a position in GSK in Q1 2024 and has held it in 10 quarters since. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • AQR Capital Management held 346,157 shares of GSK worth $18.1M as of Q2 2026.
  • AQR Capital Management bought 63,034 GSK shares in Q2 2026, an estimated $3.33M.
  • GSK made up 0.01% of AQR Capital Management's portfolio in Q2 2026, its #1234 holding.
  • AQR Capital Management first reported a position in GSK in Q1 2024 and has held it in 10 quarters since.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.